Casgevy approval (Dec 2023) was the threshold event. Research tool → approved therapeutic. Sickle cell first; oncology + ag pipeline next.
Early · 2012-
early
accelerating
peak
declining
§ The wedge — what we think vs consensus
Pending author input.
Contrarian read not yet authored for this shift. The wedge section will name the consensus position, our differing read, and the structural reason for the divergence.
§ Thesis
What's actually shifting.
CRISPR-Cas9 (and now base editors, prime editors, Cas12, Cas13) crossed the research-to-therapeutic threshold with FDA approval of Casgevy (Vertex / CRISPR Therapeutics) for sickle cell disease in December 2023. The 2020s is the platform-extension phase: in vivo delivery solves, oncology applications mature, crop-genomics scales (especially outside US/EU), and reimbursement frameworks for $2-3M one-time cures stabilize. The structural shift is gene editing becoming another tool in the medicine toolbox, not a single-disease bet — analogous to monoclonal antibodies' transition from novelty to standard modality in the 2000s.
§ Stage history
How it got here.
2012
pre-shift
Charpentier-Doudna paper. CRISPR-Cas9 demonstrated as gene-editing tool.
2017-2020
early
First clinical trials. Cas9 patent disputes (Broad vs UC).
2020
early
Charpentier + Doudna Nobel Prize; mainstreaming.
2023-Dec
early
FDA approves Casgevy for sickle cell — first CRISPR therapeutic anywhere.
Ag-biotech with CRISPR-edited crops (Pairwise, Yield10, Cibus)
Specialty-pharma manufacturing for gene therapies
Genetic-screening / diagnostics partners
Oncology platforms integrating CRISPR with CAR-T / cell therapies
Trapped sectors
Generic-drug companies in genetic-disease therapeutic categories
Symptomatic-treatment franchises in newly-curable diseases
Animal-husbandry / industrial-ag without genetics platform exposure
Long-tail rare-disease drug developers (now competing with one-time cures)
§ Named positions — specific entities
Where the categorical reads land in particular names.
Specific named positions not yet authored. This section will carry tickers / companies / asset-class names with thesis, risk, and sizing notes — the difference between a category read and a position read.
§ Signal tracking
What would tell you the shift is accelerating — or stalling.
Watch for (acceleration)
In vivo CRISPR delivery solving (currently mostly ex vivo — limits applications)
First $100M+ Casgevy quarter — commercialization velocity
Quantitative watch metrics not yet authored. This section will carry specific named metrics with their threshold levels and current values — the at-a-glance dashboard that turns a description into a tracker.
Key differenceCRISPR is a general-purpose biological tool; Internet was a general-purpose information tool. Adoption arc 10x longer because biology is regulated. Boom-bust dynamics may compress less aggressively.
§ Related Lab findings
Where the mechanism is rigorously tested.
No Lab finding has been authored on this shift yet. The shift is tracked here as macro frame; rigorous mechanism testing comes when a finding is registered against the corpus.
§ Cross-shift interactions
Where this shift compounds or conflicts with another.
AI-driven protein design (AlphaFold lineage) accelerates target identification and guide-RNA optimization.
§ Track record
Prior calls + outcomes for this shift.
No prior calls logged for this shift yet. The track record builds over time as predictions resolve. It’s the credibility ledger — visible past calls and their outcomes, same way the Lab corpus tracks pre-registered predictions.